Personalized radiation plus immunotherapy and chemo for metastatic colorectal cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of ultra-precise radiation therapy, immunotherapy, chemotherapy, and targeted therapy for people with metastatic colorectal cancer that has a normal DNA mismatch repair system. The goal is to see if this personalized approach can better control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your cancer is a type called MSS or pMMR colorectal adenocarcinoma that has spread to other parts of the body.
- You have up to 10 metastatic spots that can all be safely treated with radiation.
- If you haven't had chemotherapy for metastatic disease before, you can join one group; if you've had one line of chemo and it stopped working or caused bad side effects, you can join another group.
- You have not received any radiation therapy in the last 6 months.
- You have not had immunotherapy with a checkpoint inhibitor before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of standard chemotherapy, radiation therapy, and an immunotherapy drug (toripalimab) for people with metastatic colorectal cancer. It aims to see if adding radiation therapy and immunotherapy can help shrink tumors and improve outcomes.
This trial tests a combination of targeted radiation therapy, an immune-boosting drug, and two chemotherapy drugs for colorectal cancer that has spread or come back after two rounds of prior treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of short-course radiation, chemotherapy (CAPOX), and an immunotherapy drug (sintilimab) before surgery for people with locally advanced colon cancer that is not the highly unstable type. The goal is to see if this approach can safely spare more of the lymph nodes while still treating the cancer effectively.
This trial tests a new approach for advanced colorectal cancer that has spread and is no longer responding to standard chemotherapy. It combines two types of radiation (one high dose, one low dose) with an immunotherapy drug and a targeted therapy (TKI) to see if this can help shrink tumors and improve outcomes.
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
Hear when a new Microsatellite Stable Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.